Cytokine Signalling Forum

Publications





March 21

Estudio de Seguridad Comparativa Pos-Aprobación de Tofacitinib y Fármacos Biológicos Antirreumáticos Modificadores de la Enfermedad: Resultados de 5 años de un Registro de Artritis Reumatoide basado en los Estados Unidos

Kremer JM, Bingham CO 3rd, Cappelli LC, Greenberg JD, Madsen AM, Geier J, Rivas JL, Onofrei AM, Barr CJ, Pappas DA, Litman HJ, Dandreo KJ, Shapiro AB, Connell CA, Kavanaugh A.
ACR Open Rheumatol. 2021 Feb 11.

Analysis from the US Corrona RA registry has provided the longest-term real-world safety data for a JAK inhibitor to date. The analysis showed that the cohorts had similar adverse events, except for higher herpes zoster rates for tofacitinib initiators vs bDMARDs. Kremer JM, et al. analysed adult patients with RA newly initiating tofacitinib, or a bDMARD, to compare incidence rates of MACE, SIEs, HZ, malignancies and death. VTE data were also collected prospectively and assessed descriptively t...

Keywords: JAK, Tofacitinib, Clinical